Lori Michelle Burtz Laffel, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 107 | 2013 | 3449 | 6.440 |
Why?
|
| Blood Glucose Self-Monitoring | 31 | 2012 | 475 | 2.250 |
Why?
|
| Blood Glucose | 58 | 2023 | 6421 | 2.170 |
Why?
|
| Hypoglycemic Agents | 25 | 2023 | 3108 | 1.650 |
Why?
|
| Hypoglycemia | 15 | 2023 | 896 | 1.550 |
Why?
|
| Insulin | 32 | 2012 | 6602 | 1.140 |
Why?
|
| Patient Compliance | 16 | 2012 | 2697 | 1.110 |
Why?
|
| Parents | 15 | 2013 | 3594 | 0.940 |
Why?
|
| Diabetic Nephropathies | 19 | 2012 | 974 | 0.860 |
Why?
|
| Diabetic Ketoacidosis | 6 | 2008 | 252 | 0.780 |
Why?
|
| Self Care | 10 | 2012 | 800 | 0.760 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2023 | 12250 | 0.680 |
Why?
|
| Parent-Child Relations | 8 | 2010 | 772 | 0.660 |
Why?
|
| Adolescent | 96 | 2023 | 89046 | 0.660 |
Why?
|
| Insulin Infusion Systems | 12 | 2012 | 221 | 0.650 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2023 | 317 | 0.620 |
Why?
|
| Patient Education as Topic | 8 | 2012 | 2337 | 0.610 |
Why?
|
| Attitude to Health | 5 | 2013 | 2023 | 0.570 |
Why?
|
| Family Conflict | 4 | 2012 | 95 | 0.550 |
Why?
|
| Child | 78 | 2023 | 80771 | 0.550 |
Why?
|
| Monitoring, Ambulatory | 7 | 2011 | 357 | 0.520 |
Why?
|
| Quality of Life | 18 | 2012 | 13485 | 0.510 |
Why?
|
| Albuminuria | 9 | 2010 | 658 | 0.490 |
Why?
|
| Dietary Carbohydrates | 2 | 2009 | 896 | 0.460 |
Why?
|
| Renal Circulation | 9 | 2005 | 288 | 0.450 |
Why?
|
| Parenting | 5 | 2010 | 708 | 0.410 |
Why?
|
| Overweight | 4 | 2013 | 2448 | 0.390 |
Why?
|
| Ketones | 4 | 2009 | 183 | 0.380 |
Why?
|
| Deoxyglucose | 1 | 2011 | 322 | 0.360 |
Why?
|
| Self-Help Groups | 1 | 2012 | 194 | 0.350 |
Why?
|
| Renin-Angiotensin System | 6 | 2005 | 736 | 0.350 |
Why?
|
| Diabetes Mellitus | 6 | 2009 | 5886 | 0.340 |
Why?
|
| Play and Playthings | 1 | 2010 | 85 | 0.340 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2009 | 43 | 0.340 |
Why?
|
| Health Status | 4 | 2012 | 4091 | 0.320 |
Why?
|
| Communication Aids for Disabled | 1 | 2009 | 56 | 0.310 |
Why?
|
| Family Nursing | 2 | 2011 | 20 | 0.310 |
Why?
|
| Food Preferences | 1 | 2012 | 397 | 0.310 |
Why?
|
| Goals | 1 | 2013 | 717 | 0.290 |
Why?
|
| Energy Intake | 2 | 2013 | 2145 | 0.290 |
Why?
|
| Electronics, Medical | 1 | 2007 | 70 | 0.280 |
Why?
|
| Captopril | 6 | 2005 | 261 | 0.280 |
Why?
|
| Feeding Behavior | 4 | 2012 | 3207 | 0.280 |
Why?
|
| Electronic Mail | 1 | 2009 | 215 | 0.280 |
Why?
|
| Male | 89 | 2013 | 364203 | 0.270 |
Why?
|
| Perception | 2 | 2013 | 1205 | 0.270 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 806 | 0.270 |
Why?
|
| Female | 93 | 2013 | 396660 | 0.270 |
Why?
|
| Glyburide | 1 | 2007 | 117 | 0.270 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2007 | 144 | 0.270 |
Why?
|
| Manuals as Topic | 1 | 2006 | 99 | 0.260 |
Why?
|
| Humans | 131 | 2023 | 767040 | 0.260 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2006 | 72 | 0.260 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2006 | 101 | 0.250 |
Why?
|
| Prediabetic State | 1 | 2011 | 547 | 0.240 |
Why?
|
| Patient Satisfaction | 6 | 2012 | 3488 | 0.240 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 1738 | 0.240 |
Why?
|
| Diet | 3 | 2012 | 8089 | 0.230 |
Why?
|
| Cooperative Behavior | 2 | 2008 | 1512 | 0.230 |
Why?
|
| Adolescent Behavior | 2 | 2009 | 1188 | 0.230 |
Why?
|
| Metformin | 1 | 2012 | 908 | 0.230 |
Why?
|
| Computers, Handheld | 1 | 2006 | 211 | 0.220 |
Why?
|
| Brain Edema | 1 | 2008 | 601 | 0.220 |
Why?
|
| Medication Adherence | 3 | 2011 | 2191 | 0.220 |
Why?
|
| Ketone Bodies | 2 | 2000 | 76 | 0.210 |
Why?
|
| Diet Records | 3 | 2012 | 425 | 0.200 |
Why?
|
| Point-of-Care Systems | 2 | 2011 | 1217 | 0.200 |
Why?
|
| Kidney Failure, Chronic | 2 | 2012 | 2495 | 0.200 |
Why?
|
| Antiporters | 3 | 1992 | 275 | 0.200 |
Why?
|
| Case Management | 1 | 2003 | 277 | 0.190 |
Why?
|
| Disease Management | 3 | 2008 | 2531 | 0.190 |
Why?
|
| Hyperglycemia | 10 | 2009 | 1388 | 0.180 |
Why?
|
| Psychometrics | 5 | 2012 | 3060 | 0.180 |
Why?
|
| Kidney Glomerulus | 1 | 2003 | 571 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2005 | 1515 | 0.170 |
Why?
|
| Multivariate Analysis | 9 | 2012 | 12069 | 0.170 |
Why?
|
| Young Adult | 17 | 2012 | 59980 | 0.170 |
Why?
|
| Cystic Fibrosis | 2 | 2008 | 1292 | 0.170 |
Why?
|
| Cross-Sectional Studies | 13 | 2013 | 26325 | 0.160 |
Why?
|
| Vitamin D Deficiency | 1 | 2009 | 1389 | 0.160 |
Why?
|
| Treatment Outcome | 14 | 2023 | 65295 | 0.160 |
Why?
|
| Caregivers | 3 | 2010 | 2302 | 0.160 |
Why?
|
| Adult | 57 | 2013 | 223317 | 0.150 |
Why?
|
| Cost of Illness | 2 | 2011 | 1951 | 0.150 |
Why?
|
| Cognition Disorders | 1 | 2012 | 3968 | 0.150 |
Why?
|
| Monitoring, Physiologic | 4 | 2012 | 1794 | 0.140 |
Why?
|
| Diabetic Retinopathy | 7 | 2000 | 1300 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2009 | 4054 | 0.140 |
Why?
|
| Anxiety | 1 | 2012 | 4670 | 0.140 |
Why?
|
| Patient Care Team | 3 | 2012 | 2516 | 0.140 |
Why?
|
| Affect | 1 | 2004 | 1494 | 0.140 |
Why?
|
| Tetrazoles | 7 | 2005 | 923 | 0.130 |
Why?
|
| Reproducibility of Results | 9 | 2012 | 20169 | 0.130 |
Why?
|
| Renin | 6 | 2005 | 647 | 0.130 |
Why?
|
| Body Image | 2 | 2012 | 646 | 0.130 |
Why?
|
| Body Mass Index | 7 | 2013 | 13048 | 0.130 |
Why?
|
| Automation | 3 | 2009 | 587 | 0.120 |
Why?
|
| Insulin, Long-Acting | 2 | 2012 | 59 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2013 | 4881 | 0.120 |
Why?
|
| Prevalence | 5 | 2013 | 15851 | 0.120 |
Why?
|
| Biphenyl Compounds | 7 | 2005 | 1026 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2006 | 3232 | 0.120 |
Why?
|
| Exercise | 2 | 2010 | 5954 | 0.120 |
Why?
|
| Antihypertensive Agents | 3 | 2003 | 2030 | 0.110 |
Why?
|
| Depression | 4 | 2010 | 8234 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2012 | 24299 | 0.110 |
Why?
|
| Cohort Studies | 13 | 2012 | 41718 | 0.110 |
Why?
|
| Erythrocytes | 4 | 1992 | 2411 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7435 | 0.100 |
Why?
|
| Double-Blind Method | 5 | 2023 | 12451 | 0.100 |
Why?
|
| Age of Onset | 4 | 2007 | 3344 | 0.100 |
Why?
|
| Benzimidazoles | 5 | 2005 | 862 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2003 | 2780 | 0.100 |
Why?
|
| Hospitalization | 5 | 2007 | 10815 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2012 | 54886 | 0.100 |
Why?
|
| Family Relations | 2 | 2004 | 318 | 0.090 |
Why?
|
| Follow-Up Studies | 8 | 2012 | 39317 | 0.090 |
Why?
|
| Patient-Centered Care | 2 | 2011 | 1444 | 0.090 |
Why?
|
| Self Efficacy | 2 | 2012 | 643 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 4855 | 0.090 |
Why?
|
| Menu Planning | 1 | 2010 | 29 | 0.090 |
Why?
|
| Incidence | 5 | 2012 | 21526 | 0.090 |
Why?
|
| Time Factors | 10 | 2013 | 40154 | 0.080 |
Why?
|
| Fruit | 2 | 2012 | 1165 | 0.080 |
Why?
|
| Vegetables | 2 | 2012 | 1199 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 7 | 2005 | 2227 | 0.080 |
Why?
|
| Social Support | 2 | 2010 | 2192 | 0.080 |
Why?
|
| Glutamate Decarboxylase | 1 | 2010 | 239 | 0.080 |
Why?
|
| Injections, Subcutaneous | 2 | 2008 | 685 | 0.080 |
Why?
|
| Angiotensin II | 3 | 2004 | 842 | 0.080 |
Why?
|
| Child, Preschool | 11 | 2011 | 42606 | 0.080 |
Why?
|
| Sick Leave | 1 | 2009 | 105 | 0.080 |
Why?
|
| Problem Solving | 2 | 2008 | 442 | 0.080 |
Why?
|
| Coma | 1 | 2012 | 485 | 0.080 |
Why?
|
| United States | 12 | 2012 | 72971 | 0.080 |
Why?
|
| Markov Chains | 1 | 2012 | 976 | 0.080 |
Why?
|
| Risk | 4 | 2011 | 9606 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2012 | 1741 | 0.070 |
Why?
|
| Ergocalciferols | 1 | 2009 | 110 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 1531 | 0.070 |
Why?
|
| Blood Pressure | 8 | 2005 | 8531 | 0.070 |
Why?
|
| Sodium | 2 | 1992 | 1594 | 0.070 |
Why?
|
| Postprandial Period | 1 | 2009 | 320 | 0.070 |
Why?
|
| Random Allocation | 1 | 2012 | 2394 | 0.070 |
Why?
|
| Albumins | 1 | 2010 | 577 | 0.070 |
Why?
|
| Proteinuria | 6 | 2000 | 613 | 0.070 |
Why?
|
| Body Weight | 3 | 2013 | 4627 | 0.070 |
Why?
|
| Office Visits | 2 | 2003 | 595 | 0.070 |
Why?
|
| Pilot Projects | 5 | 2012 | 8732 | 0.070 |
Why?
|
| Family Characteristics | 1 | 2012 | 1002 | 0.070 |
Why?
|
| Blindness | 1 | 2011 | 585 | 0.070 |
Why?
|
| Sunlight | 1 | 2009 | 337 | 0.070 |
Why?
|
| Life Change Events | 1 | 2012 | 956 | 0.070 |
Why?
|
| Risk Factors | 13 | 2012 | 74886 | 0.070 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 15645 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2011 | 969 | 0.070 |
Why?
|
| Child Health Services | 1 | 2011 | 645 | 0.060 |
Why?
|
| Ketosis | 2 | 2007 | 46 | 0.060 |
Why?
|
| Creatinine | 4 | 2001 | 1916 | 0.060 |
Why?
|
| Vitamin E | 2 | 2000 | 872 | 0.060 |
Why?
|
| Middle Aged | 24 | 2013 | 223233 | 0.060 |
Why?
|
| Motivation | 2 | 2012 | 2021 | 0.060 |
Why?
|
| Age Factors | 5 | 2010 | 18401 | 0.060 |
Why?
|
| Glycogen Storage Disease Type I | 2 | 1997 | 53 | 0.060 |
Why?
|
| Retinal Vessels | 2 | 2000 | 863 | 0.060 |
Why?
|
| Emergency Service, Hospital | 4 | 2007 | 7871 | 0.060 |
Why?
|
| Obesity | 4 | 2013 | 13085 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2007 | 1181 | 0.060 |
Why?
|
| Cholecalciferol | 1 | 2009 | 558 | 0.050 |
Why?
|
| Boston | 4 | 2012 | 9360 | 0.050 |
Why?
|
| Prognosis | 4 | 2012 | 29963 | 0.050 |
Why?
|
| Patient Preference | 1 | 2011 | 947 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2009 | 848 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2005 | 325 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2001 | 748 | 0.050 |
Why?
|
| Sexual Maturation | 1 | 2004 | 258 | 0.050 |
Why?
|
| Contraceptives, Oral | 1 | 2005 | 560 | 0.050 |
Why?
|
| Psychology | 1 | 2004 | 353 | 0.050 |
Why?
|
| Vasoconstriction | 1 | 2005 | 591 | 0.050 |
Why?
|
| Carrier Proteins | 3 | 1992 | 4925 | 0.050 |
Why?
|
| Siblings | 1 | 2006 | 828 | 0.050 |
Why?
|
| Weight Gain | 1 | 2012 | 2360 | 0.050 |
Why?
|
| Probability | 1 | 2007 | 2476 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2010 | 2114 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2012 | 7848 | 0.050 |
Why?
|
| Puberty | 1 | 2004 | 501 | 0.050 |
Why?
|
| Interviews as Topic | 3 | 2011 | 2741 | 0.050 |
Why?
|
| Infant | 6 | 2011 | 36485 | 0.050 |
Why?
|
| Hypertension | 5 | 1992 | 8615 | 0.040 |
Why?
|
| Acrylates | 1 | 2000 | 75 | 0.040 |
Why?
|
| Weight Loss | 1 | 2012 | 2716 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 2001 | 238 | 0.040 |
Why?
|
| Child Nutritional Physiological Phenomena | 2 | 2012 | 294 | 0.040 |
Why?
|
| Health Surveys | 1 | 2009 | 4056 | 0.040 |
Why?
|
| Seizures | 1 | 2012 | 2996 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 3 | 2011 | 5537 | 0.040 |
Why?
|
| Aldosterone | 1 | 2004 | 881 | 0.040 |
Why?
|
| Proxy | 2 | 2011 | 150 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 3928 | 0.040 |
Why?
|
| Apolipoproteins E | 2 | 1996 | 1459 | 0.040 |
Why?
|
| Family Health | 1 | 2003 | 1254 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 15424 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2012 | 6260 | 0.040 |
Why?
|
| Family | 2 | 2010 | 3210 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 988 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2011 | 2817 | 0.040 |
Why?
|
| Forecasting | 1 | 2007 | 2936 | 0.040 |
Why?
|
| Patient Selection | 4 | 2012 | 4256 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2007 | 2209 | 0.040 |
Why?
|
| Radiography | 1 | 2008 | 6975 | 0.040 |
Why?
|
| Logistic Models | 2 | 2010 | 13284 | 0.040 |
Why?
|
| Decision Making | 1 | 2011 | 3951 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2004 | 1432 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2000 | 680 | 0.030 |
Why?
|
| Pediatrics | 1 | 2011 | 3621 | 0.030 |
Why?
|
| Thiophenes | 1 | 2000 | 570 | 0.030 |
Why?
|
| Marital Status | 2 | 2009 | 426 | 0.030 |
Why?
|
| Counseling | 1 | 2003 | 1553 | 0.030 |
Why?
|
| Kidney | 3 | 2000 | 7063 | 0.030 |
Why?
|
| Diabetes Complications | 3 | 2009 | 1319 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2003 | 2505 | 0.030 |
Why?
|
| Mothers | 1 | 2005 | 2209 | 0.030 |
Why?
|
| Vasodilation | 1 | 1999 | 968 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2003 | 6310 | 0.030 |
Why?
|
| Imidazoles | 1 | 2000 | 1169 | 0.030 |
Why?
|
| Comorbidity | 1 | 2009 | 10582 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2009 | 4526 | 0.030 |
Why?
|
| Mass Screening | 1 | 2009 | 5456 | 0.030 |
Why?
|
| Longitudinal Studies | 4 | 2011 | 14766 | 0.030 |
Why?
|
| Kidney Function Tests | 2 | 2005 | 683 | 0.030 |
Why?
|
| p-Aminohippuric Acid | 2 | 2005 | 36 | 0.030 |
Why?
|
| Massachusetts | 1 | 2006 | 8890 | 0.030 |
Why?
|
| Glucose | 2 | 1997 | 4341 | 0.030 |
Why?
|
| Methods | 1 | 1992 | 1065 | 0.020 |
Why?
|
| Health Behavior | 1 | 2003 | 2650 | 0.020 |
Why?
|
| Regional Blood Flow | 3 | 2000 | 1479 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 1936 | 0.020 |
Why?
|
| Lithium | 2 | 1992 | 600 | 0.020 |
Why?
|
| Ion Transport | 1 | 1992 | 322 | 0.020 |
Why?
|
| Starch | 1 | 1990 | 81 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 1729 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2010 | 70 | 0.020 |
Why?
|
| Aged | 9 | 2011 | 171319 | 0.020 |
Why?
|
| Educational Status | 2 | 2009 | 2511 | 0.020 |
Why?
|
| Reference Values | 2 | 2011 | 4918 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2012 | 740 | 0.020 |
Why?
|
| Disabled Children | 1 | 2011 | 250 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 15925 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2012 | 467 | 0.020 |
Why?
|
| Linear Models | 2 | 2012 | 5875 | 0.020 |
Why?
|
| Illness Behavior | 1 | 2008 | 23 | 0.020 |
Why?
|
| C-Peptide | 1 | 2010 | 443 | 0.020 |
Why?
|
| Cooking | 1 | 2010 | 327 | 0.020 |
Why?
|
| Diuretics | 1 | 1991 | 614 | 0.020 |
Why?
|
| Disease Progression | 3 | 2007 | 13646 | 0.020 |
Why?
|
| Adaptation, Psychological | 2 | 2008 | 2662 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 1002 | 0.020 |
Why?
|
| Glucagon | 1 | 2009 | 534 | 0.020 |
Why?
|
| Family Therapy | 1 | 2008 | 214 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2007 | 152 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2008 | 5311 | 0.020 |
Why?
|
| New England | 1 | 2010 | 1058 | 0.020 |
Why?
|
| Community Health Services | 1 | 2011 | 659 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2009 | 400 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 1997 | 2099 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 1999 | 3446 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2008 | 6215 | 0.020 |
Why?
|
| Health Resources | 1 | 2011 | 948 | 0.020 |
Why?
|
| Education | 1 | 2008 | 531 | 0.020 |
Why?
|
| Kinetics | 1 | 1992 | 6287 | 0.010 |
Why?
|
| Smoking | 1 | 2001 | 9081 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2850 | 0.010 |
Why?
|
| Child Behavior | 1 | 2010 | 864 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2011 | 2428 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 2005 | 326 | 0.010 |
Why?
|
| Focus Groups | 1 | 2010 | 1460 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 2010 | 1350 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 1326 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 1405 | 0.010 |
Why?
|
| Cross-Over Studies | 2 | 2000 | 2105 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 654 | 0.010 |
Why?
|
| Angiotensin I | 1 | 2002 | 47 | 0.010 |
Why?
|
| Behavior Therapy | 1 | 2008 | 886 | 0.010 |
Why?
|
| Hemodynamics | 2 | 2005 | 4186 | 0.010 |
Why?
|
| Puerperal Disorders | 1 | 2005 | 304 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1994 | 8535 | 0.010 |
Why?
|
| Parity | 1 | 2005 | 931 | 0.010 |
Why?
|
| Age Distribution | 1 | 2007 | 2870 | 0.010 |
Why?
|
| Disease Susceptibility | 3 | 1996 | 1791 | 0.010 |
Why?
|
| Regression Analysis | 2 | 2001 | 6331 | 0.010 |
Why?
|
| Electrochemistry | 1 | 2001 | 144 | 0.010 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2004 | 428 | 0.010 |
Why?
|
| Cholesterol | 3 | 1996 | 2905 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4572 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2011 | 3964 | 0.010 |
Why?
|
| DNA | 1 | 1993 | 7210 | 0.010 |
Why?
|
| Angiotensinogen | 1 | 1999 | 161 | 0.010 |
Why?
|
| Inulin | 1 | 1999 | 67 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 361 | 0.010 |
Why?
|
| Self Concept | 1 | 2005 | 1041 | 0.010 |
Why?
|
| Glucose Clamp Technique | 1 | 1999 | 262 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2007 | 3154 | 0.010 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1999 | 279 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1992 | 5914 | 0.010 |
Why?
|
| Pregnancy | 1 | 1999 | 30238 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 622 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2000 | 892 | 0.010 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1999 | 291 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2011 | 4306 | 0.010 |
Why?
|
| Aging | 3 | 2005 | 8729 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2011 | 8068 | 0.010 |
Why?
|
| Triglycerides | 2 | 1996 | 2444 | 0.010 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2002 | 1065 | 0.010 |
Why?
|
| Growth | 1 | 1997 | 366 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2001 | 1110 | 0.010 |
Why?
|
| Sodium, Dietary | 1 | 1999 | 426 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 10393 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 2174 | 0.010 |
Why?
|
| Physicians | 1 | 2011 | 4593 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 1993 | 148 | 0.010 |
Why?
|
| Equipment Design | 1 | 2001 | 3489 | 0.010 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1993 | 111 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2007 | 3986 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2005 | 3591 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 12793 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 12986 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 1991 | 6573 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 1623 | 0.010 |
Why?
|
| Lactates | 1 | 1990 | 398 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1992 | 18063 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1996 | 3621 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1990 | 572 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1988 | 323 | 0.000 |
Why?
|
| Animals | 1 | 1999 | 168965 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 10748 | 0.000 |
Why?
|
| Exons | 1 | 1993 | 2391 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2004 | 22254 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1990 | 2478 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 14672 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1996 | 4247 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1992 | 2350 | 0.000 |
Why?
|
| Alleles | 1 | 1996 | 6893 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2005 | 26396 | 0.000 |
Why?
|
| Uric Acid | 1 | 1990 | 805 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6067 | 0.000 |
Why?
|
| Odds Ratio | 1 | 1995 | 9660 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1990 | 1840 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 6507 | 0.000 |
Why?
|
| Genotype | 1 | 1996 | 13035 | 0.000 |
Why?
|
| Lipids | 1 | 1991 | 3322 | 0.000 |
Why?
|
| Coronary Vessels | 1 | 1991 | 3114 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2007 | 81659 | 0.000 |
Why?
|
| Survival Rate | 1 | 1991 | 12823 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2001 | 59548 | 0.000 |
Why?
|